Ipsen S.A. publishes its 2023 Half-Year Financial Report

Regulated Information 07 May 2024 5 mins read

Ipsen S.A. – Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting

Regulated Information 06 May 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital

Corporate 24 April 2024 7 mins read

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

Announcement 22 April 2024 5 mins read

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

Regulated Information 17 April 2024 4 mins read

Ipsen publishes its 2023 Universal Registration Document

Regulated Information 08 April 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital

Announcement 02 April 2024 7 mins read

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Regulated Information 07 March 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital

Corporate 15 February 2024 1 mins read

Ipsen S.A. publishes its 2023 Consolidated Financial Statements

Corporate 13 February 2024 14 mins read

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA